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The absence of early diagnostic markers contributes to delays in the diagnosis of SS, and there is a well-recognised need for the identification and validation of biomarkers to be used in diagnosis, prognostic assessments, as a research tool and probably to identify novel targets for therapeutic intervention in SS. The evaluation of the composition of saliva, which can be non-invasively collected, could provide biomarkers for SS. 2 Changes in salivary proteins can reflect the pathogenesis of SS, as salivary glands are the major source of salivary proteins and a major site of autoimmune destruction; saliva is therefore an appropriate body fluid for biomarkers of SS. 3 There is a 1000-fold increased risk of lymphoma development in parotid glands from patients with SS. 4 Parotid saliva is therefore a valuable substrate that might be used to differentiate between different subgroups of patients with SS; those at higher risk of developing mucosa-associated lymphoid tissue lymphoma (MALT-L) and those who have developed MALT-L.
Since the first proteomics study on parotid saliva of patients with SS in 1999 by Beeley and Khoo, 5 salivary proteomics has remained one of the most promising approaches to human disease biomarker identification with the advantage of being non-invasively sampled. Several proteomics studies have shown differential protein expression in the saliva of patients with SS and healthy control subjects, 6, 7 and some studies have validated candidate markers. 8 A few studies have performed proteomics analysis of saliva samples from patients with lymphoma. 9, 10 In this study, it was hypothesised that SS-related proteins exist in human saliva and could be used to discriminate patients with SS from control subjects. Furthermore, identified salivary biomarkers could be useful in identifying a subgroup of SS who may be at higher risk of developing or who already have developed lymphoma.
To address the study aims, a proteomics analysis of parotid saliva samples from healthy subjects, patients with SS and patients with SS at higher risk of developing lymphoma was undertaken and potential protein biomarkers identified. A candidate biomarker (S100A8/A9
heterodimer) was selected and validated by immunoassay of larger groups of samples including disease (dry mouth) control subjects and patients with SS who have developed lymphoma. The marker was further tested on whole mouth saliva (WMS), and differences between both types of saliva were compared.
| MATERIALS AND METHODS

| Study group
The protocol for this study was reviewed and approved by the National Research Ethics Service (NRES) Committee (11/LO/1121).
Patients with symptomatic dry mouth attending Guy's and St. Thomas's Hospital Oral Medicine department (GSTT NHS Foundation Trust) were included. Recruited patients were originally classified using the American-European Consensus Group (AECG) criteria.
11
Later, patients were reclassified according to the ACR criteria, 12 and some were included as patients with SS in this study (total n = 51; mean age ± SEM, 52.3 ± 1.6). Patients with Sjögren's syndrome were further subgrouped into three groups:
1. SS-M patients who had been diagnosed with a MALT lymphoma (M), which had been confirmed by histopathological assessment of biopsies of parotid glands, minor salivary glands or submandibular gland (n = 14; mean age ± SEM, 53.7 ± 2.6).
2. SS at-risk group: patients with SS classified as high risk of developing MALT-L (SS-HR, n = 18; mean age ± SEM, 51.9 ± 3), on the basis of three or more markers of severe SS (parotid enlargement, cryoglobulinaemic vasculitis, hypocomplementaemia, cryoglobulinaemia, high focus score, germinal centre in their biopsy and previous lymphoma), and SS-LR classified as low-risk patients with less than three markers but could be associated with other generalised inflammatory factors including raised β2 microglobulin levels, lymphopenia and hypergammaglobulinaemia. 13 SS-LR (n = 19; mean age ± SEM, 51.5 ± 2.7).
3. SS subgroup (n = 19; mean age ± SEM, 51.5 ± 2.7) who were not considered at risk of developing MALT nor developed it.
Nineteen of the 51 patients with SS were determined to have another autoimmune disease (eg, rheumatoid arthritis, systemic lupus erythematosus and scleroderma, see Table S1 ). Dry mouth patients complaining of xerostomia with hyposalivation, with a negative serology test for SS while having non-specific sialadenitis on their biopsy results and confirmed nodal osteoarthritis, were diagnosed as SNOX 14 and were included as a disease control patient group (n = 14; mean age ± SEM, 62.7 ± 2.6). A further control group was formed from healthy subjects not taking medication, with no complaints of oral or ocular dryness and no oral mucosal diseases (n = 18; mean age ± SEM, 50.7 ± 2.6).
| Collection of parotid and whole mouth salivas
Unstimulated whole mouth saliva (WMS) samples were collected over 10 minutes followed by stimulated parotid saliva samples over 10 minutes. All saliva samples were immediately placed on ice and transferred to the laboratory where they were processed by centrifugation at 9500 g for 10 minutes (WMS) and 5 minutes (parotid saliva). Samples were split into a number of aliquots and stored at −80°C until required. None of the aliquots were used more than once per assay. A minimum of 1 hour fasting preceded all sample collections, which were undertaken between 09.00 and 12.00 hour.
Detailed protocols of saliva collection, flow rates and total protein concentrations (Bicinchoninic Acid assay; Thermo Scientific, Rockford, IL, USA) are described in Supporting Information 2, 3 and 4.
| Proteomics analysis of parotid saliva
A pilot proteomics analysis was performed on parotid salivas from patients with SS to identify potential biomarkers associated with parotid gland involvement and an increased risk of developing MALT-L.
Parotid salivas from healthy subjects (n = 2), patients with SS (n = 2) and patients with SS at risk of developing MALT-L (n = 2) were subjected to a proteomics analysis using LDS gel electrophoresis fol- 
| Enzyme-linked immunosorbent assay (ELISA)
Commercially available pre-coated plates (Quantikine ELISA Kit, R&D Systems, Minneapolis, MN, USA), (cat. no. DS8900) for S100A8/ JAZZAR ET AL.
| 901 S100A9 heterodimer were used for both parotid saliva and WMS. The samples were thawed and diluted at an optimised dilution factor of 1/ 500 for WMS and 1/200 for parotid saliva. Standards and samples were loaded in duplicate. Incubations were carried out at room temperature on a horizontal orbital microplate shaker. All materials were supplied with the kit, and the manufacturer's instructions were followed.
| Data analysis
All results were exported to Windows ® Excel 2007 spreadsheets, statistical analyses for ELISA data were carried out using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA),
and GraphPad Prism ® 6 (GraphPad Software Inc., San Diego, CA, USA) was used for the graphical presentation. The Kruskal-Wallis test followed by Dunn's post hoc test was used to determine the differences between groups when comparing the mean amount of S100A8/S100A9 present in the salivary samples of the five different groups of participants. A study with 80% power and an effect size of 0.42 was determined to require a total sample of 75 (15 per group) for comparison of the protein levels at a 5% level of significance using a two-tailed test (G*power version 3.1.5 software). The median and quartiles were used as estimates of central tendency and dispersion. The significance level was set to P < 0.05. 
| Proteomics analysis of parotid saliva
Four upregulated proteins; actin cytoplasmic 2, Ig γ-1chain C region, S100-A8 and S100-A9 were finally selected as candidate biomarkers ( Figure S1 ). S100-A9 was not present in the healthy control subject sample in the first run while present in both disease samples. When comparing both disease samples of SS at MALT-L risk and SS-only patients, both S100-A8 and S100-A9 were increased by twofold in both runs (Figure 2 ).
3.3 | Salivary S100A8/A9 levels
| Parotid saliva
The median concentration (Q1-Q3) of S100A8/A9 in parotid saliva from overall patients with SS was 743.1 (91-3526) ng/mL, which was significantly higher than concentrations in healthy (31.9; 0-273.2 ng/ mL) and disease control (208.9; 0-265.3 ng/mL) subjects ( Figure 3A ).
The median concentration of S100A8/A9 in the whole group of patients with SS was 506 (84.6-1031) ng/mL. The mean concentra- Two patients in the SS-HR group presented with unilateral parotid swelling and the S100A8/A9 levels were compared between salivas from the right and left parotid glands of the same patient (n = 2). Higher levels were detected in salivas from the swollen side for both patients (Table S2 ). The higher S100A8/A9 levels were confirmed when the samples were assayed a second time.
| Whole mouth saliva
The median (Q1-Q3) S100A8/A9 concentration was 20-fold higher in WMS from the overall SS group (16 628; 3165-20 184 ng/mL) compared with parotid saliva. There was no statistically significant difference with concentrations of S100A8/A9 in WMS from the healthy (8457; 687.3-17 154 ng/mL) and disease control (3857; 2418-8697 ng/mL) groups ( Figure 3C ). However, SS subgroups did show significantly higher levels, and also the median concentration in SS-M patients (22 545; 16 032-28 096 ng/mL) was higher than the healthy control group (P = 0.046), SNOX group (P = 0.009) and the SS subgroup (5244; 1550-17 225 ng/mL; P = 0.049; Figure 3D ).
In both parotid and WMS, there were no statistically significant (Mann-Whitney U test) differences detected between patients with or without another autoimmune disease (AID; Figure 3A ,C), although a few subjects with high concentrations had another AID. No statistically significant (Mann-Whitney U test) differences were detected between patients at high and low risk of developing lymphoma (Figure 3B,D) .
| Sensitivity and reproducibility of S100A8/A9 immunoassay
The accuracy of the ELISA was tested for whole mouth saliva (n = 1) and parotid saliva (n = 2) by spiking samples with a known concentration of S100A8/A9. The mean recovery (accuracy) of the three samples was 107.7% and ranged between 80.5% and 142.9%. The linearity was reported by the manufacturer (spiked whole mouth saliva) (n = 4) with a range of 92%-115% for dilutions 1:2, 1:4, 1:8 and 1:16 ( Figure S2 ).
The reproducibility (intra-assay precision) of ELISA was determined as the mean coefficient of variation (CV) of five replicates of three samples (positive parotid saliva) in one assay ( Table 1 ). The interassay precision was 8.2% using two samples tested on six separate plates, and these were comparable to the values reported by the manufacturer (2.7%-4.5% for the intra-assay CV and 3.2%-5.8%
for the interassay CV).
| Associations of S100A8/A9 levels in whole mouth and parotid saliva and their relation to their flow rates
There was a weak positive correlation between the salivary levels of S100A8/A9 in matched parotid and WMS from the same patients (n = 56; Spearman's r = 0.268, P = 0.046; Figure 4) . A stronger correlation was found when only SS subgroups were analysed (n = 26;
Spearman's r = 0.496, P = 0.01). A significant correlation was not found in samples from healthy control subjects (n = 18; Spearman's r = 0.106, P = 0.67). There was a negative (inverse) correlation between the parotid salivary levels of S100A8/A9 and parotid flow rates (Spearman's r = 0.256, P = 0.02) but not with whole mouth saliva flow rates (Spearman's r = 0.138, P = 0.309).
| DISCUSSION
Results from the pilot proteomics analysis of parotid saliva suggested that levels of S100A8 (Calgranulin A) and S100A9 (Calgranulin B) not only discriminate between SS and healthy controls, but also between patients with SS MALT-L and those without lymphoma.
F I G U R E 2
The most overexpressed proteins in patients with SS compared to control subjects, as determined by proteomics analysis of parotid saliva samples. A, Three proteins in the first run *, B, four proteins in the second run. The process of selection involved comparison of relative expression levels (fold change ratio) of proteins identified by proteomics analysis between control samples and samples from patients with SS at risk of developing MALT-L and between control samples and SS samples. A secondary comparison of proteins was performed after log (log2) transformation of the raw ratios. A final comparison between both runs was performed following their individual analysis where differences between both disease samples (SS and SS at risk) were identified. SS, Sjögren's syndrome MALT-L risk, patients with SS at risk of developing mucosa-associated lymphoid tissue lymphoma. *Protein S100-A9 was not detected in the control sample
This suggests the possibility that S100A8/A9 might act as a biomarker for the development of lymphoma. S100-A8 and S100-A9 are myeloid-related pro-inflammatory members of the alarmin family and are predominantly found as a S100A8/A9 24 kD heterodimer that plays a prominent role in the regulation of chronic and acute inflammation, inducing leucocyte chemotaxis and adhesion. S100A8/A9 has been reported as being upregulated in different cancers, 15, 16 and increased S100A9 protein expression is linked with autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. 17 Results from the subsequent immunoassay of larger numbers of parotid salivas supported and extended the proteomics findings, showing increased expression of S100A8/A9 in parotid saliva of SS groups compared with both healthy controls and non-SS dry mouth (SNOX) disease controls. A higher proportion of parotid salivas from the MALT-L-associated SS groups showed concentrations above 2000 ng/mL, but the median values were not statistically significantly different from the SS group without MALT-L association. Interestingly, it was noted that, when comparing left and right glands of two patients at risk of developing MALT-L, the swollen glands showed increased level of S100A8/A9 compared to the contralateral unswollen gland, which suggested that increased S100A8/A9 expression reflects a localised inflammatory activity.
Levels of S100A8/A9 in WMS were higher than parotid saliva but did not show statistically significant increases in SS compared with the healthy and disease controls. A possible explanation is that, despite being strict in selecting age-matched healthy controls who were not on any xerostogenic medication, it might be that other influences on oral health status (eg, caries) affected S100A8/A9 T A B L E 1 Intra-assay precision of S100A8/A9 ELISA assay tested on parotid saliva levels in whole mouth saliva. Other sources, in particular gingival crevicular fluid, contribute to S100A8/A9 in WMS, and it should be noted that almost a third of the SS subjects were not able to produce whole mouth saliva. Subgrouping of SS has revealed significant differences in whole mouth S100A8/A9 levels of MALT-L patients when compared to the other subgroups. This may be related to the important link of S100A8/A9 to cancer as an amplifier of inflammation-associated tumour development, which has been previously reported. 15, 16 As the total protein concentration of whole mouth saliva tended to increase in SS associated with MALT-L compared to other groups, a comparison of S100A8/A9 levels between the groups was made after adjusting the values to total protein (ng/mg) but the higher levels in MALT-L remained significant.
The results from previous studies [18] [19] [20] [21] [22] [23] of salivary S100A8/A9 levels in healthy control and SS subjects are summarised in Table 2 .
Most previously published studies in SS have assayed stimulated WMS and the mean values in control subjects are higher than the present study, which utilised unstimulated WMS. Readings comparable to those of the present study were obtained by Sweet et al 18 showing a wide range of S100A8/A9 levels in unstimulated WMS (200-18 000 ng/mL) but significantly higher concentrations in patients with SS, a finding in contrast to the present study. While
Cuida et al 23 did not show a significant difference in parotid salivary S100A8/A9 between SS and control subjects, they did report a positive correlation between parotid salivary levels and minor salivary gland focus scores of patients with SS. In our study, a group of non-SS sicca disease control subjects diagnosed with non-specific sialadenitis, nodal osteoarthritis and xerostomia (SNOX) was included. SNOX has been little studied since its first description by Kassimos et al, 14 and later by others, 24, 25 it was therefore of interest to follow this disease group further. SNOX is often confused with SS and is sometimes incorrectly called pre-SS and shares some symptoms; fatigue, complaints and signs of dry mouth and dry eyes;
inflammation of the minor salivary glands (non-specific vs focal in SS groups). Levels of S100A8/A9 in the SNOX group were not significantly elevated in parotid saliva and WMS compared with healthy control subjects, which suggested that the sialadenitis and degree of parotid inflammation in SNOX patients is less than in patients with SS.
A potential limitation of the present study is that some patients with MALT-L were receiving immunosuppressive therapy. However, a comparison of treated and untreated patients did not show a difference in mean S100A8/A9 levels ( Figure S3 ). This might also be due to insufficient power of the study to determine an effect of drugs in this heterogeneous group of patients. Furthermore, the small sample size of the proteomics analysis should be noted and it would be of great significance to conduct the same comparison on a larger group of patients to check for the reproducibility of the results.
This study supports previous reports indicating the value of saliva as a diagnostic tool for assessing disease activity and progression in Sjögren's syndrome. The preliminary results of parotid saliva proteomics analyses provided a list of candidate biomarkers of SS and SS at risk of lymphoma. It may be that a combination of S100A8/A9
with another parotid salivary molecular or other biomarkers, for example parotid ultrasonography (Jazzar et al, submitted), could provide a more robust diagnostic tool.
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